News Feed Item

MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds

EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings.

MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year.  The symposium begins today, April 23, 2014, and concludes on April 27, 2014.

"We are pleased that two abstracts highlighting EpiFix® allografts were selected for oral presentation and one of them, authored by Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder, DPM, MSc, CWS, was selected as 3rd place for Best Oral Abstract," said Parker H. "Pete" Petit, CEO of MiMedx Group, Inc.  (NASDAQ: MDXG).

"Clinically, EpiFix® is associated with more rapid healing and prevention of longer term complications including infection and amputation," said Dr. Stephen Bergquist, Medical Director for Jackson-Madison County Hospital.  "From the cost-of-care perspective, EpiFix requires the use of fewer grafts leading to overall cost savings," he continued.

Abstracts presenting EpiFix® studies and cases are:

  • A Prospective, Randomized, Comparative Study of Weekly vs. Bi-weekly Application of Dehydrated Human Amnion/Chorion Membrane Allograft in the Management of Diabetic Foot Ulcers (Abstract #CR_055, Zelen, Serena, Snyder) demonstrated in a 12-week study period of 40 patients with a mean time to complete healing of 2.4 weeks for weekly application of EpiFix® vs. 4.1 wks for biweekly application of EpiFix®.  This shows using EpiFix® weekly heals DFUs almost twice as fast as biweekly applications of EpiFix®. Overall complete heal rate with EpiFix® in both arms was 92.5% (37/40) at 12 weeks.


  • A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers (Abstract #CS_139,Serena,  Fetterolf , Harris, Doner, Patel, Connell, DeMarco, LE, McConnell , Lullove, Taffe.) 90 patients were enrolled to date in this ongoing trial. At time of interim analysis 68 patients had completed the study: 44 ulcers were randomized to receive dHACM (1 or 2 applications) and 24 received SOC alone. Outcomes were similar within the dHACM group.  At 4 weeks, 63.6% of wounds in the dHACM  group, and 25.0% of the standard of care group demonstrated greater than 40% wound closure at 4 weeks (p=0.0023). After 4 weeks ulcers treated with dHACM had reduced by 48.9% vs 12.0% for those treated with SOC only, p=0.003.


  • Treatment of Stage III and Stage IV Pressure Ulcers with Dehydrated Human Amnion/Chorion Membrane (Abstract #CS_014, Bergquist) evaluated the clinical and cost effectiveness of dHACM allografts as a treatment for Stage III and IV pressure ulcers (PUs).   In Stage III cases and Stage IV cases,  PUs of varying sizes were completely healed within weeks (from 1 week for  Stage III PUs with wound size of 8.6cm2 and 2.53 cm2, to 8 weeks for a Stage IV PU with an initial wound size of 9.2 cm2 ). Cost effectiveness of dHACM for treatment of PUs was influenced by increased healing rates, velocity of healing and subsequent reduction in risk for complications.  Wound size-appropriate grafts further reduce waste and cost per treatment. 


  • Human Amniotic Membrane Allograft to Treat Diabetic Foot Ulcers with Exposed Bone and Tendon   (Abstract# CS_117 Pougatsch, Shum, Belczyk, Rogers) 5 consecutive diabetic neuropathic patients exhibiting wounds with exposed bone and tendon were treated with EpiFix® with the intent to gain as much coverage over the exposed deep structures in as little time as possible in preparation for split-thickness skin grafting. All 5 patients had sufficiently developed granulation tissue overlying bone and tendon structures and were ready for split-thickness skin grafting in an average of 15 days (range 9-22). 4 patients healed the split-thickness skin grafts.


"These data support our previously published studies relating to the significant role for EpiFix® in advanced wound care," said Bill Taylor, President and COO of MiMedx. MiMedx is the leading developer and manufacturer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

MiMedx is exhibiting at the conference (booth 1506), and will host In-Booth Education with speakers Steve Bergquist, MD presenting on 'Complex wounds and pressure ulcer treatment with EpiFix', and Donna Becker, MSN, ACNP-BC who will discuss 'Clinical experiences with dHACM.'  Drs. Robert Snyder, Chuck Zelen, Matthew Garoufalis and Thomas Serena will be presenting about Wound Regeneration at a Company-sponsored symposium.

About EpiFix®

EpiFix® is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix® dehydrated human amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix® minimizes graft waste.  The Company's PURION® Process combines cleaning, dehydration and sterilization, making EpiFix® a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER give you detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPO also offers s...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
The IoT Will Grow: In what might be the most obvious prediction of the decade, the IoT will continue to expand next year, with more and more devices coming online every single day. What isn’t so obvious about this prediction: where that growth will occur. The retail, healthcare, and industrial/supply chain industries will likely see the greatest growth. Forrester Research has predicted the IoT will become “the backbone” of customer value as it continues to grow. It is no surprise that retail is ...
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
How is DevOps going within your organization? If you need some help measuring just how well it is going, we have prepared a list of some key DevOps metrics to track. These metrics can help you understand how your team is doing over time. The word DevOps means different things to different people. Some say it a culture and every vendor in the industry claims that their tools help with DevOps. Depending on how you define DevOps, some of these metrics may matter more or less to you and your team.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of bus...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...